Clinical forecasting is now leveraging innovative informatics capabilities for more precise recruitment and endpoint projections during a study’s crucial…


Medivation opens its books to would-be buyers, including the formerly hostile Sanofi

British watchdogs suspend Astellas UK after investigations, audits, and a crackdown from Japanese HQ

NIH won't override patents on Astellas' pricey Xtandi to bring down prices

Most-wanted buyout target Medivation and hostile bidder Sanofi line up for board fight

Xarelto, Xtandi surge toward Europe's best-selling ranks, with Opdivo close behind

Sanofi’s weak Q1 cancer drug sales spur Medivation buyout desire

UPDATED: Sanofi may spark a Medivation bidding war with $9.3B bid